1-3 of 3
Cesar R. Gonzalez-Bonilla, MD, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Rituximab Sensitizes TRAIL-Resistant B-NHL Lines to Apoptosis by Both TRAIL and Fully Humanized Antibodies Targeting TRAIL-R1 (Mapatumumab) and TRAIL-R2 (Lexatumumab).

Mario I. Vega, PhD, Sara Huerta-Yepez, PhD, Stavroula Baritaki, PhD, Melisa A. Martinez-Paniagua, McS, Cesar R. Gonzalez-Bonilla, MD, PhD, Benjamin Bonavida, PhD
Journal: Blood
Blood (2007) 110 (11): 2350.
https://doi.org/10.1182/blood.V110.11.2350.2350
Published: 2007
Journal Articles

Cytotoxicity of Genetically Engineered Fusion Protein with CD154 Peptide Mimetic (OmpC-CD154 p ) on B-NHL Cell Lines.

Bernardo Martinez-Miguel, Melisa A. Martinez-Paniagua, McS, Sara Huerta-Yepez, PhD, Rogelio Hernandez-Pando, MD PhD, Cesar R. Gonzalez-Bonilla, MD PhD, Benjamin Bonavida, PhD, Mario I. Vega, PhD
Journal: Blood
Blood (2007) 110 (11): 4525.
https://doi.org/10.1182/blood.V110.11.4525.4525
Published: 2007
Journal Articles

Direct and Enhanced Cytotoxicity of the Bcl-2 Family Inhibitor GX15-070 on Rituximab-Sensitive and Rituximab-Resistant B-NHL Clones.

Melisa A. Martinez-Paniagua, McS, Mario I. Vega, PhD, Sara Huerta-Yepez, PhD, Bernardo Martinez-Miguel, Rogelio Hernandez-Pando, MD PhD, Cesar R. Gonzalez-Bonilla, MD PhD, Benjamin Bonavida, PhD
Journal: Blood
Blood (2007) 110 (11): 1402.
https://doi.org/10.1182/blood.V110.11.1402.1402
Published: 2007